EVAX Share Price Performance
US$3.15
0.11 (3.62%)
84.4% undervalued intrinsic discount
US$20.25
Fair Value
Price US$3.15
Talos US$20.25
AnalystConsensusTarget US$11.25
AnalystLowTarget US$9.00
Fair ValueUS$20.25
Share Pricen/a
Evaxion A/S Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
EVAX Community Narratives
TA
Fair Value
·Fair Value US$20.25 84.4% undervalued intrinsic discount
The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$11.25 72.0% undervalued intrinsic discount
AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$9 65.0% undervalued intrinsic discount
AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)
Evaxion Biotech is a micro-cap TechBio company punching significantly above its weight class. While the market views it as a small preclinical player, its proprietary AI-Immunology™ platform has already secured a massive validation: a partnership with Merck (MSD).Read more
AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value
A big drugmaker’s deal to advance one of Evaxion’s AI-designed vaccine projects puts a spotlight on whether its technology can turn into real partnerships and cash, not just promising lab results. With several cancer vaccine programs moving forward and new tools meant to speed up development, the upside depends on more partners buying in—and the downside is setbacks, slow adoption, or shareholder dilution.Read more
AN
US$16
80.3% undervalued intrinsic discount
Fair Value
Profit Margin
33.99%
Future PE
10.62x
Price in 2029
US$10.68
AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity
A small biotech aims to turn its vaccine design software into big pharma partnerships, with early cancer vaccine results and a recent licensing deal helping it look like a more credible partner. The upside depends on whether its next studies and newer cancer targets hold up—and whether it can keep funding the work without giving away too much to new investors.Read more
AN
US$11.25
72.0% undervalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
34.62x
Price in 2029
US$7.52
AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience
Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?Read more
AN
US$9
65.0% undervalued intrinsic discount
Fair Value
Profit Margin
36.25%
Future PE
6.31x
Price in 2029
US$6.21
Trending Discussion
No trending discussion available.
Recently Updated Narratives
TA
The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)
Fair Value: US$20.25 84.4% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential
Fair Value: US$16 80.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential
Fair Value: US$11.25 72.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Evaxion A/S Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 20, 2026
- -1.17
- 100.00%
- -129.60%
- 0%
About EVAX
- Founded
- 2008
- Employees
- 46
- CEO
- WebsiteView website
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
